Drugs / sulperazone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT05925309 Background | Jul 2023 → Dec 2027 expected | biliary atresia, cholangitis | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sulperazone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05925309 ↗ |
| Route | Intravenous | “Sulperazone 50mg/kg q8h is used intravenously” NCT05925309 ↗ |